This is a phase II SBIR Contract to develop broad spectrum monoclonal antibodies against enteroviruses. EV-D68 causes respiratory and neurological diseases mainly in young children and implicated to be a major cause for acute flaccid myelitis (AFM). There are no therapeutics or vaccines against EV-D68. EV-D68 is a member of picornavirus family, a priority pathogen because of their high pandemic potential.